Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents. Kiselev, O., Vasin, A., Shevyryova, M., Deeva, E., Sivak, K., Egorov, V., Tsvetkov, V., Egorov, A., Romanovskaya-Romanko, E., Stepanova, L., Komissarov, A., Tsybalova, L., & Ignatjev, G. Molecular Biology, 49(4):480-493, Maik Nauka Publishing / Springer SBM, 2015. cited By 3
Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents [link]Paper  doi  abstract   bibtex   
Ebola hemorrhagic fever (EHF) epidemic currently ongoing in West Africa is not the first among numerous epidemics in the continent. Yet it seems to be the worst EHF epidemic outbreak caused by Ebola virus Zaire since 1976 as regards its extremely large scale and rapid spread in the population. Experiments to study the agent have continued for more than 20 years. The EHF virus has a relatively simple genome with seven genes and additional reading frame resulting from RNA editing. While being of a relatively low genetic capacity, the virus can be ranked as a standard for pathogenicity with the ability to evade the host immune response in uttermost perfection. The EHF virus has similarities with retroviruses, but belongs to (–)RNA viruses of a nonretroviral origin. Genetic elements of the virus, NIRV, were detected in animal and human genomes. EHF virus glycoprotein (GP) is a class I fusion protein and shows more similarities than distinctions in tertiary structure with SIV and HIV gp41 proteins and even influenza virus hemagglutinin. EHF is an unusual infectious disease, and studying the molecular basis of its pathogenesis may contribute to new findings in therapy of severe conditions leading to a fatal outcome. © 2015, Pleiades Publishing, Inc.
@ARTICLE{Kiselev2015480,
author={Kiselev, O.I. and Vasin, A.V. and Shevyryova, M.P. and Deeva, E.G. and Sivak, K.V. and Egorov, V.V. and Tsvetkov, V.B. and Egorov, A.Y. and Romanovskaya-Romanko, E.A. and Stepanova, L.A. and Komissarov, A.B. and Tsybalova, L.M. and Ignatjev, G.M.},
title={Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents},
journal={Molecular Biology},
year={2015},
volume={49},
number={4},
pages={480-493},
doi={10.1134/S002689331504007X},
note={cited By 3},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939146460&doi=10.1134%2fS002689331504007X&partnerID=40&md5=834035e73c6aa0e53773fa87a0e7b7bb},
affiliation={Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376, Russian Federation; St. Petersburg State Polytechnic University, St. Petersburg, 195251, Russian Federation; Ministry of Health of the Russian Federation, Moscow, 127994, Russian Federation; Topchiev Institute of Petrochemical Synthesis, Moscow, 119991, Russian Federation},
abstract={Ebola hemorrhagic fever (EHF) epidemic currently ongoing in West Africa is not the first among numerous epidemics in the continent. Yet it seems to be the worst EHF epidemic outbreak caused by Ebola virus Zaire since 1976 as regards its extremely large scale and rapid spread in the population. Experiments to study the agent have continued for more than 20 years. The EHF virus has a relatively simple genome with seven genes and additional reading frame resulting from RNA editing. While being of a relatively low genetic capacity, the virus can be ranked as a standard for pathogenicity with the ability to evade the host immune response in uttermost perfection. The EHF virus has similarities with retroviruses, but belongs to (–)RNA viruses of a nonretroviral origin. Genetic elements of the virus, NIRV, were detected in animal and human genomes. EHF virus glycoprotein (GP) is a class I fusion protein and shows more similarities than distinctions in tertiary structure with SIV and HIV gp41 proteins and even influenza virus hemagglutinin. EHF is an unusual infectious disease, and studying the molecular basis of its pathogenesis may contribute to new findings in therapy of severe conditions leading to a fatal outcome. © 2015, Pleiades Publishing, Inc.},
author_keywords={antiviral drugs;  Ebola virus;  genome;  hemorrhagic fever;  interferon antagonists;  vaccines},
correspondence_address1={Vasin, A.V.; Institute of Influenza, Ministry of Health of the Russian FederationRussian Federation},
publisher={Maik Nauka Publishing / Springer SBM},
issn={00268933},
language={English},
abbrev_source_title={Mol. Biol.},
document_type={Review},
source={Scopus},
}

Downloads: 0